首页> 美国卫生研究院文献>World Journal of Gastroenterology >Prognostic angiogenic markers (endoglin VEGF CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors
【2h】

Prognostic angiogenic markers (endoglin VEGF CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors

机译:胃肠道间质瘤的预后性血管生成标记物(endoglinVEGFCD31)和肿瘤细胞增殖(Ki67)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To evaluate the correlation between the immunoexpression of angiogenic markers [CD31, CD105 and vascular endothelial growth factor (VEGF)], proliferative index (Ki67), and prognosis of patients with gastrointestinal stromal tumors (GIST).METHODS: This is a retrospective study of 54 GIST cases. Medical records were searched to obtain the GIST patients’ demographic and clinical data, and paraffin-embedded blocks of tumor samples were retrieved from the hospital archives to conduct a new immunohistochemical evaluation. The tumor samples of GIST patients were subject to immunohistochemical evaluation for endoglin (CD105), CD31, VEGF, and Ki67 expression. The CD105 and CD31 intratumoral microvascular density (IMVD) was measured using automated analysis. We determined the correlation between the immunoexpression of CD105, CD31, VEGF, Ki67 and prognosis. In addition, we conducted a cutoff analysis using the receiver-operating characteristic curve. VEGF positivity was classified as either null/weak or strong. Ki67 was evaluated using a cutoff of 5% positive cells. The prognosis was classified as good (patient alive without recurrence) or poor (patient with recurrence/death).RESULTS: The distribution of tumor sites among the 54 analyzed samples was as follows: 27 (50%) in the stomach, 20 (37.1%) in the small intestine, 6 (11.1%) in the colon, and 1 (1.8%) in the esophagus. The size of the tumors ranged from 2 to 33 cm (median: 8 cm); in 12 cases (22.2%), the tumor was below 5 cm at the largest diameter, but in 42 cases (77.7%), the tumor was larger than 5 cm. The means of CD105 and CD31 were significantly higher in the group with poor prognosis (P < 0.001). The cut-off values of CD105 (> 1.2%) and CD31 (> 2.5%) in the receiver-operating characteristic curve were related to a poorer prognosis. Cases with a better prognosis showed significantly null/weak staining for VEGF (P < 0.001). Ki-67 expression of ≥ 5% was strongly correlated with a worse prognosis (P < 0.001). In the multivariate analysis, CD105 was the variable that most strongly correlated with prognosis.CONCLUSION: The IMVD cutoff values for the angiogenic markers CD105 and CD31, may be prognostic factors for GIST, in addition to VEGF and Ki67.
机译:目的:评估血管生成标志物[CD31,CD105和血管内皮生长因子(VEGF)]的免疫表达,增殖指数(Ki67)与胃肠道间质瘤(GIST)患者的预后之间的相关性。方法:这是一项回顾性研究。 54例GIST病例的研究。搜索病历以获得GIST患者的人口统计和临床数据,并从医院档案中检索石蜡包埋的肿瘤样本块,以进行新的免疫组化评估。对GIST患者的肿瘤样本进行免疫组化评估,评估其内皮糖蛋白(CD105),CD31,VEGF和Ki67的表达。使用自动分析测量CD105和CD31肿瘤内微血管密度(IMVD)。我们确定了CD105,CD31,VEGF,Ki67的免疫表达与预后之间的相关性。此外,我们使用接收器工作特性曲线进行了截止分析。 VEGF阳性分类为无效/弱或强。使用5%阳性细胞的临界值评估Ki67。预后分为好(无复发活着的患者)或差(有复发/死亡的患者)的预后。结果:54个分析样本中的肿瘤部位分布如下:胃中27个(50%),20个(37.1) %)在小肠中,在结肠中占6(11.1%),在食道中占1(1.8%)。肿瘤的大小为2至33厘米(中位数:8厘米)。 12例(22.2%)的肿瘤最大直径在5 cm以下,但42例(77.7%)的肿瘤大于5 cm。预后较差的组中CD105和CD31的平均值显着更高(P <0.001)。接受者操作特征曲线中CD105(> 1.2%)和CD31(> 2.5%)的临界值与较差的预后有关。预后较好的病例显示VEGF显着无效/弱染色(P <0.001)。 Ki-67≥5%的表达与不良预后密切相关(P <0.001)。在多因素分析中,CD105是与预后最密切相关的变量。结论:除VEGF和Ki67外,血管生成标记CD105和CD31的IMVD截止值可能是GIST的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号